The effects of docosahexaenoic acid supplementation on cognition and well-being in mild cognitive impairment: A 12-month randomised controlled trial

Simple item page
dc.citation.issue5
dc.citation.volume37
dc.contributor.authorMengelberg A
dc.contributor.authorLeathem J
dc.contributor.authorPodd J
dc.contributor.authorHill S
dc.contributor.authorConlon C
dc.coverage.spatialEngland
dc.date.accessioned2023-08-22T20:58:21Z
dc.date.accessioned2023-09-04T01:41:43Z
dc.date.available2022-03-12
dc.date.available2023-08-22T20:58:21Z
dc.date.available2023-09-04T01:41:43Z
dc.date.issued2022-05
dc.date.updated2023-08-22T04:28:49Z
dc.description(c) 2022 The Author/sen_US
dc.description.abstractOBJECTIVES: Several recent clinical trials have shown that docosahexaenoic acid (DHA) supplements have a significant effect on cognition in cognitively impaired older adults. This randomised controlled trial aimed to investigate the cognitive effects of a DHA fish oil supplement in older adults with mild cognitive impairment, and to examine the moderating effect of the apolipoprotein E (APOE) ɛ4 allele on cognition and well-being. METHODS/DESIGN: Seventy-two older adults between the ages of 60 and 90 from New Zealand were given a DHA supplement equivalent to 1491 mg DHA + 351 mg eicosapentaenoic acid per day or a placebo for a period of 12 months. Outcome measures included cognition, wellbeing and self-rated quality of life as well as height, weight, blood pressure and APOE genotyping. RESULTS: The final analysis (n = 60) found no evidence of a treatment effect on cognitive measures, although did find a treatment effect on systolic blood pressure (p = 0.03, ƞ2  = 0.08), and a treatment interaction for APOE ɛ4 carriers on depression (p = 0.04, ƞ2  = 0.07) and anxiety (p = 0.02, ƞ2  = 0.09) scores in favour of the DHA supplement. CONCLUSIONS: Despite no effect on cognition, the positive result in APOE ɛ4 carriers on depression and anxiety scores and on systolic blood pressure justifies further DHA trials. It may be a prudent step going forward for more studies to replicate the design elements (dose, duration and cognitive measures) of previous DHA trials to help understand why not all older adults appear to benefit from taking a fish oil supplement.
dc.description.confidentialfalse
dc.edition.editionMay 2022
dc.format.extent1-12
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/35373862
dc.identifier.citationMengelberg A, Leathem J, Podd J, Hill S, Conlon C. (2022). The effects of docosahexaenoic acid supplementation on cognition and well-being in mild cognitive impairment: A 12-month randomised controlled trial.. Int J Geriatr Psychiatry. 37. 5. (pp. 1-12).
dc.identifier.doi10.1002/gps.5707
dc.identifier.eissn1099-1166
dc.identifier.elements-typejournal-article
dc.identifier.harvestedMassey_Dark
dc.identifier.issn0885-6230
dc.identifier.urihttp://hdl.handle.net/10179/20008
dc.languageeng
dc.publisherJohn Wiley and Sons, Ltd
dc.publisher.urihttps://onlinelibrary.wiley.com/doi/10.1002/gps.5707
dc.relation.isPartOfInt J Geriatr Psychiatry
dc.rightsCC BY-NC 4.0en_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/en_US
dc.subjectAPOE ɛ4 carriers
dc.subjectDHA
dc.subjectEPA
dc.subjectmild cognitive impairment
dc.subjectAged
dc.subjectCognition
dc.subjectCognitive Dysfunction
dc.subjectDietary Supplements
dc.subjectDocosahexaenoic Acids
dc.subjectDouble-Blind Method
dc.subjectHumans
dc.subjectQuality of Life
dc.titleThe effects of docosahexaenoic acid supplementation on cognition and well-being in mild cognitive impairment: A 12-month randomised controlled trial
dc.typeJournal article
pubs.elements-id452815
pubs.organisational-groupOther
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
452815 PDF.pdf
Size:
592.37 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Journal Articles